Targets › HMPV
4 programs from 2 companies in 8 trials: 7 Phase 1, 1 Phase 2; Infectious disease, Vaccines; next expected readout Jan 2027.
Open in Phaseline: the race on HMPV, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Sanofi | Bivalent RSV+HMPV protein vaccine (RPF08203) Respiratory syncytial virus and human metapneumovirus protein vaccine | RSVA, RSVB, HMPV | Phase 2 | Respiratory Syncytial Virus | Jul 2028 |
| Sanofi | Investigational hMPV/RSV vaccine mRNA vaccine encapsulated in lipid nanoparticle targeting hMPV and RSV | HMPV, RSV | Phase 1 | Human Metapneumovirus Immunization | Jan 2027 |
| ModernaTX | mRNA-1365 (Profile 2) mRNA vaccine targeting respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) | RSV, HMPV | Phase 1 | Respiratory Syncytial Virus (RSV); Respiratory Syncytial Virus | Jul 2027 |
| Sanofi | RSV + HMPV Candidate Vaccine Live attenuated or recombinant viral vaccine against respiratory syncytial virus and human | RSV, HMPV | Phase 1 | Respiratory Syncytial Virus Immunization | May 2028 |
Human Metapneumovirus Immunization (4) Respiratory Syncytial Virus (2) Respiratory Syncytial Virus Immunization (1) Respiratory Syncytial Virus (RSV) (1)
other (4)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.